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PATENTS AND BIOTECHNOLOGY
PANEL DISCUSSION
MR. RICHARDS: I'd like to make one observation. You
condemned the European Patent Office. It's not the European
Patent Office that's the problem. The European Patent Office has
been remarkably inventive in finding its way around the problems
created by the European Patent Convention-
MR. MISROCK: It's the legislators.
MR. RICHARDS: -in method of treatment claims, animal
variety claims, plant variety claims, the computer area. Every-
where it gets the chance, the EPO minimizes the destructive effects
of the Convention as much as possible. But, it's got to go back to
the legislatures. There's nothing much more the Patent Office can
do.
MR. MISROCK: I agree. Any questions anywhere?
AUDIENCE MEMBER: I wanted to address all the panelists.
As far as morality issues in the United States, I agree with Profes-
sor Wegner and Mr. Misrock. One point, one cannot obtain a
patent for anything that impacts on nuclear energy. That's some-
thing that this country thought about a while ago.
MR. MISROCK: And that's statutory.
AUDIENCE MEMBER: That's statutory. The second issue is
that we have the NIH Guidelines on Recombinant DNA Technolo-
gy,I and that will always impact as to what direction DNA technol-
ogy goes. As a future patent attorney, I think it's an exciting field.
With the explosion in discovery going on today, we are about to
realize the dreams of yesterday's cures and the hope and reality of
curing today's diseases. I think that's an important focus.
Now, Mr. Misrock, you mentioned the Amgen2 decision, as far
as the Patent Office has said, a case where the technology was
from 1980 that you couldn't have conception or reduction of prac-
tice in a DNA sequence.
1. National Institutes of Health: Guidelines for Research Involving Recombinant
DNA Molecules, 51 Fed. Reg. 16,958 (1986).
2. Amgen, Inc. v. Chugai Pharmaceutical Co., 927 F.2d 1200 (Fed. Cir. 1991).
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MR. MISROCK: And, of course, the same judge, Judge
Lourie, writing in the recent decision of Fiers v. Sugano,3 reiterated
it and has held, of course, that you do not invent a gene-you can't
conceive a gene and you don't invent it-until you have its struc-
ture.
AUDIENCE MEMBER: That was all based on technology
from the 1980s. How would you conceive of advising your clients
today? With polymerase chain reactions, if one had a particular
sequence in a gene, might not you argue for enablement, and possi-
bly conception, of the entire sequence?
MR. MISROCK: I would argue for it. But given the fact that
I think that Judge Lourie has backed himself into a corner, and
since most of the other judges don't have the background in bio-
technology, I think that we're going to be stuck with that for some
time. It was technology in the 1980s that he was addressing, both
as to Fiers v. Sugano and Amgen.
PROFESSOR WEGNER: But there's another way of looking
at that too, isn't there? Both of those cases really stem from Oka
v. Youssefyeh, 4 involving conventional organic chemistry. Yousse-
fyeh had the structure of the compound in hand but did not have
an operative method of making that compound; it required further
invention. So what the Federal Circuit Court held in Oka v.
Youssefyeh was that until you have an operative method for making
the product in hand, you don't have a conception.
I think a good lawyer in this situation will bring in an affidavit
that can explain that his invention is operative as of the date of the
structure being shown and should be able to prevail. I would hope
he would do so at the Board of Appeals level; and if not at the
Board of Appeals level, at the Federal Circuit Court. Certainly,
one who has an affidavit that proves that this structure "X" pic-
tured at this time was operative would certainly win in the Federal
Circuit.
MR. MISROCK: Look at the mischief that was done with the
3. Fiers v. Revel, 984 F.2d 1164 (Fed. Cir. 1993).
4. 849 F.2d 581 (Fed. Cir. 1988).
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case called In re Durden.5 Durden held that a process otherwise
obvious was not rendered unobvious or nonobvious by reason of
starting with a material which didn't exist before, new starting
material. Thereafter, whether it was Group 1806 or otherwise, the
Patent Office almost cleaved into two parts: the routine application
of Durden-no process being allowed on the grounds that the ma-
nipulative steps were the same-and, on a case-by-case basis, some
examiners allowing claims when you have brought the argument
out that you could not have predicted whether or not reasonably
you were going to make molecular spaghetti or you were going to
make a particular product.
There is even proposed legislation, as there has been for some
time, that Durden ought not to be applied. I don't like to see the
statute changed on a case-by-case basis because of problems that
we're having in the Patent Office. Durden has created a lot of
mischief.
The bigger problem that I see now in the Patent Office in the
United States is Group 180 running off in its own direction with
respect to human therapy. They are taking the position that even
though you have animal tests, if you have a claim to the method
treatment of a human by giving a diseased patient a drug in a ther-
apeutic amount, et cetera, that they want human data. It started
with the AIDS cases and it has now expanded to others.
Recently, we received in our office a forty-seven-page Office
Action. I've never seen that, in thirty-eight years that I have been
in practice. I'm scandalized that this thing looks like an FDA
rejection as opposed to application of patent law. Now, I've talked
with some people who routinely practice in the Patent Office with
what I call small molecules in drugs, and those groups are acting
the way the law states. I think that issue is going to have to be
taken up to the Federal Circuit or someone is going to have to
teach a lesson to the group director to bring them in line with what
the law is on human therapy.
5. 763 F.2d 1406 (Fed. Cir. 1985).
6. Group 180 is the Biotechnology Unit of the United States Patent and Trade-
mark Office.
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PROFESSOR WEGNER: There have been several Board opin-
ions in that area.
MR. MISROCK: There are three unpublished opinions in that
area. We can't get our hands on them, but they apparently have a
policy which Group 180 has now adopted with respect to this hu-
man therapy.
PROFESSOR WEGNER: There are several more than that, I
think, and there will have to be a test case.
MR. RICHARDS: In the Proposed Directive, the comments
made by the Commission in putting it up to the Council goes to
this issue somewhat. It goes without saying that if the applicant
simply wishes to patent a mere part of the human body, per
se-e.g. a human gene-neither the function of which nor the
protein for which it codes is known, the exclusion of patentability
will apply. This is clearly a blow to the NIH and its Human Ge-
nome Project.
But, I think that it does point out that if you know what the
gene codes for, then you essentially know how to make it because
if you know what the amino acid sequence is, you know what the
DNA sequence is, and you can use a gene machine to synthesize
it.
MR. MISROCK: But, John, I have taken the position that
utility generally is easy to obtain in the United States. If it makes
a protein, you can always eat it as a food; if you do that, that
should meet the utility requirement of the statute.
MR. RICHARDS: But not all proteins are nontoxic.
MR. MISROCK: Well, then the patent's invalid.
PROFESSOR WEGNER: On the question of Durden, there is
a Senate bill that was introduced February 3, 1993 that has cleared
the Senate subcommittee. 7 There is also-and again, I don't want
to get involved in my own cases-but I have a test case that was
argued November 2, 1992 called In re Ochiai8 which directly chal-
7. S. 298, 103d Cong., 1st Sess. (1993).
8. No. 92-1446 (Fed. Cir.), on appeal from, No. 92-2372 (Bd. Pat. App. & Inter-
ferences July 8, 1992).
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lenges Durden. That case is awaiting a decision.
MR. MISROCK: With respect to morality, Oreste, we have no
statutory provision that something is not patentable because of
public policy or it being immoral. I will tell you, though, that in
thirty-eight years this has been the law in the United States.
I take the position, for example, that the patentability of ani-
mals ought not to be restricted, that there is a rule of reason about
what you can get. I have used-and I hope you don't mind my
facetious statement-but suppose that somebody took a pitbull and
they took the eight-cell embryo of the pitbull and they moved in
bovine growth hormone so we now have a pitbull that grows to the
size of a cow-a cow-sized pitbull. Thereafter, that same genius
took the eight-cell embryo of that cow-sized pitbull and moved in
the genes from a viper so that when the pitbull grew up it was
poisonous, so you have a poisonous cow-sized pitbull. Is there a
need for it? Maybe some drug dealers up in Harlem, would like
cow-sized poisonous pitbulls for protection or something like that.
There's not the slightest doubt in my mind that the Patent Of-
fice-and if not the Patent Office, the courts-would refuse to
issue a patent on this subject matter because it's against the public
policy of the United States, without it being enunciated by statute.
It just makes sense. So I don't see the need for a statute with
respect to the patentability of animals or transgenic animals, partic-
ularly when they have utility and use for the treatment of human
disease, not just production of more milk or something like that.
MR. RICHARDS: I think we would probably all agree with
that. One thing I can't understand with what's going on in Europe
at the moment is why the prohibition on plant varieties remains.
The UPOV Convention itself was amended to permit protection of
plant varieties.
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